文献速递胸部肿瘤头颈与中枢神经肿瘤

纳武利尤单抗扩展准入项目中非鳞非小细胞肺癌意大利队列的真实世界结果

Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2019-10-28

该研究纳入意大利153个中心1588例经治晚期非鳞NSCLC患者,接受纳武利尤单抗3 mg/kg每2周治疗至多24个月。总缓解率18%、疾病控制率44%,中位总生存11.3个月(95%CI 10.2-12.4),老年及中枢神经系统转移患者亚组疗效与总体相似。

要点

  • 意大利真实世界队列中纳武利尤单抗总缓解率18%、疾病控制率44%,中位总生存11.3个月。
  • ≥70岁和≥75岁老年患者疗效与总体人群相似,支持老年患者使用。
  • 中枢神经系统转移患者中位总生存8.6个月,1年总生存率43%。

核心结论

  • 这是迄今规模最大的纳武利尤单抗真实世界临床经验,支持其用于经治非鳞NSCLC,包括高龄或中枢神经系统转移患者。

研究设计与样本

  • 全球纳武利尤单抗扩展准入项目的意大利队列,纳入153个中心1588例经治晚期非鳞NSCLC患者。
  • 患者接受纳武利尤单抗3 mg/kg每2周,最长24个月,收集疗效和安全性数据。

主要发现

  • 总缓解率18%,疾病控制率44%,中位总生存11.3个月(95%CI 10.2-12.4)。
  • 老年患者(≥70岁 n=522;≥75岁 n=232)疗效与总体研究人群相似。
  • 中枢神经系统转移患者(n=409)中位总生存8.6个月(95%CI 6.4-10.8),1年总生存率43%。
  • 276例(26%)患者进展后继续接受纳武利尤单抗,其中57例获得后续疾病控制;该组中位总生存16.2个月(95%CI 14.0-18.4),1年总生存率62%。

临床怎么用

  • 经治晚期非鳞NSCLC可考虑使用纳武利尤单抗,老年及中枢神经系统转移患者也可从治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non-small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression. METHODS: Pretreated patients with advanced non-squamous NSCLC received nivolumab at 3 mg/kg every 2 weeks up to 24 months. Efficacy data (investigator-assessed tumour response, progression date and survival) and safety data were collected. FINDINGS: 1588 patients were treated across 153 Italian centres. Overall response rate and disease control rate were 18% and 44%, respectively; median overall survival (OS) was 11.3 months (95% CI: 10.2-12.4). Elderly patients (≥70 n = 522; ≥75 n = 232) achieved outcomes similar to the global study population; patients with CNS metastases (n = 409) had an OS of 8.6 months (95% CI: 6.4-10.8), and a 1-year OS rate of 43%. Nivolumab was administered beyond progression to 276 patients (26%), 57 of whom achieved subsequent disease control; the median OS of patients receiving nivolumab beyond progression was 16.2 months (95% CI: 14.0-18.4), while 1-year OS rate was 62%. INTERPRETATION: To date, this is the largest clinical experience with nivolumab in a real-world setting. Our data support its use in clinical practice for pretreated non-squamous NSCLC, including patients with older age or CNS metastases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Grossi F, Genova C, Crinò L, et al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur J Cancer. 2019. PMID: 31671314. doi:10.1016/j.ejca.2019.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。